Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 5 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Immatics Biotechnologies GmbH has 11 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 10 distinct examiners and 6 distinct art units, showing a broad prosecution footprint across the company’s current docket. The examiner spread is wider than the art-unit spread, so several matters are being examined within overlapping technical groupings.
REDDIG, PETER J is the busiest examiner, with 2 pending matters. That concentration is limited relative to the full docket, while the remaining actions are distributed among other examiners. Counsel should therefore preserve matter-specific analysis while looking for recurring issues within the shared art-unit structure.
The breadth of assignment makes centralized docket oversight important. Different examiner practices may require tailored amendment and interview planning, while the repeated art-unit allocation may support identifying common claim-scope or prior-art themes. The current data supports coordination across the portfolio, but it does not establish that the same substantive issue appears in each action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 4 (40%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 3 (30%) |
| No statute on record | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 2 | 58.0% | +40.2% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| SANG, HONG | 1 | 54.9% | +62.8% |
| ESSEX, LAURA ANN | 1 | 60.0% | +35.8% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 64.3% | +41.7% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18323577 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | YOUTCHOM PENDIE, EMMANUEL LED | 34d |
| 18451216 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | NICKOL, GARY B | 69d |
| 18647837 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | OUSPENSKI, ILIA I | — |
| 18642871 | NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME | REDDIG, PETER J | — |
| 18533733 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS | SANG, HONG | — |
| 18529656 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | ESSEX, LAURA ANN | — |
| 18505361 | METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF | REDDIG, PETER J | — |
| 18345700 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1643 | 3 |
| 1644 | 2 |
| 1649 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647837 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18642871 | NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME | REDDIG, PETER J | 1646 | Other | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18533733 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS | SANG, HONG | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18529656 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | ESSEX, LAURA ANN | 1649 | §112Other | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18505361 | METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF | REDDIG, PETER J | 1646 | §103DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18451216 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | NICKOL, GARY B | 1643 | §112Other | Final Rejection | 69d | Pending | Aug 17, 2023 |
| 18345700 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | CANELLA, KAREN A | 1643 | §112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18343502 | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | SKELDING, ZACHARY S | 1644 | §112Other | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18323577 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | Other | Non-Final OA | 34d | Pending | May 25, 2023 |
| 18052009 | RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE | DUFFY, BRADLEY | 1643 | DP | Final Rejection | — | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmatics Biotechnologies GmbH has 10 pending office actions as of October 2026, spread across 5 art units and 9 examiners.
Peter J Reddig has the most, with 2 of Immatics Biotechnologies GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
